BSX (Boston Scientific) Debt-to-Equity : 0.53 (As of Mar. 2025)

View and export this data going back to 1992. Start your Free Trial

What is Boston Scientific Debt-to-Equity?

Boston Scientific's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $777 Mil. Boston Scientific's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $10,931 Mil. Boston Scientific's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $22,212 Mil. Boston Scientific's debt to equity for the quarter that ended in Mar. 2025 was 0.53.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Boston Scientific's Debt-to-Equity or its related term are showing as below:

BSX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.49 Med: 0.68 Max: 1.12
Current: 0.53

During the past 13 years, the highest Debt-to-Equity Ratio of Boston Scientific was 1.12. The lowest was 0.49. And the median was 0.68.

BSX's Debt-to-Equity is ranked worse than
70.44% of 697 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs BSX: 0.53

Boston Scientific Debt-to-Equity Historical Data

The historical data trend for Boston Scientific's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Debt-to-Equity Chart

Boston Scientific Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.62

0.57

0.53

0.49

0.51

Boston Scientific Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Equity	Get a 7-Day Free Trial															0.55	0.54	0.54	0.51	0.53

Competitive Comparison of Boston Scientific's Debt-to-Equity

For the Medical Devices subindustry, Boston Scientific's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boston Scientific's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Boston Scientific's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Boston Scientific Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Boston Scientific's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1778	+	9369)	/	21770
	=	0.51

Boston Scientific's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(777	+	10931)	/	22212
	=	0.53

Boston Scientific (NYSE:BSX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Boston Scientific Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Boston Scientific Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BSX:Mexico 1BSX:Italy 0HOY:UK BSX:Germany BSX:Germany BSX:Germany B1SX34:Brazil BSXC:Austria

Address

300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234

Website

https://www.bostonscientific.com

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Executives

Vance R Brown	officer: SVP, GC and Corp. Secretary	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
John Bradley Sorenson	officer: SVP, Glob Ops & Qual	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Arthur C Butcher	officer: SVP&Pres, Endoscopy	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Michael F Mahoney	officer: President	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Jeffrey B. Mirviss	officer: SVP&Pres, Periph Intervent	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Ellen M Zane	director	C/O TUFTS-NEW ENGLAND MEDICAL CENTER, 750 WASHINGTON STREET, TUFTS-NEMC #451, BOSTON MA 02111
Daniel J. Brennan	officer: EVP and CFO	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Edward J Ludwig	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Joseph Michael Fitzgerald	officer: SVP & President, Endovascular	C/O BOSTON SCIENTIFIC, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Wendy Carruthers	officer: SVP, Human Resources	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Thepaut Eric Francis Yves	officer: SVP & Pres, Europe	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Susan E Morano	director	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Jessica L Mega	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jonathan Monson	officer: VP, Corp Controller and CAO	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752